Inogen price target lowered to $8 from $15 at Stifel

Stifel analyst Mathew Blackman lowered the firm’s price target on Inogen to $8 from $15 and keeps a Hold rating on the shares. The company’s Q2 results were “weaker-than-expected” and its FY23 outlook was “significantly muted,” the analyst tells investors. While there are small signs of stability/improvement, the firm needs to see “less-noisy” quarters to be more confident in the model, Stifel says.